Kintor Pharma-B (09939): KT-939 Receives Notice of Invention Patent Grant

Zhitong Finance APP News, Kintor Pharma-B (09939) announced that on October 21, 2026, the Group received a Notice of Grant of Invention Patent issued by the China National Intellectual Property Administration for its independently developed novel high-efficiency tyrosinase inhibitor KT-939 (Chinese trade name: OXIMIDOLKT-939, English trade name: OXIMIDOLKT-939), which inhibits melanin production. The patent relates to a tyrosinase inhibitor and its use (application number: 202580002670.3). Suzhou Kintor Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, submitted a request for prioritized examination on March 27, 2026, and was granted prioritized examination by the China National Intellectual Property Administration on June 12, 2026. From the submission of the prioritized examination request to the issuance of the Notice of Grant of Invention Patent, the process took approximately 6 months.